Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3045 in Moderate to Severe Active Rheumatoid Arthritis
NCT07233655Phase 2Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of shr-3045 in rheumatoid arthritis (RA), sponsored by Hengrui Therapeutics. Started Jan 2026; status: active, not recruiting.
02
Drugs
shr-3045
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07233655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233655.